The active ingredient in Ozempic was associated with a 40% to 70% lower risk of a first-time Alzheimer's diagnosis in diabetes patients.

Published in Alzheimer’s & Dementia on Thursday, Oct. 24, the study found that semaglutide — the active ingredient in popular weight loss drugs like Ozempic and Wegovy — may be linked to lower risks of Alzheimer's disease in people with type 2 diabetes.

Semaglutide medications — such as Ozempic, the popular diabetes medication — have been linked to a reduced risk of Alzheimer’s disease for certain groups, a new study finds.